



Medicsight Unveils New Version of ColonCAD(TM) at ECR 2009

NEW YORK, March 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE Alternext US: MGT) and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, is pleased to announce it has launched ColonCAD API 4.0, the latest version of its computer-aided detection software, today at the European Congress of Radiology (ECR 2009) show in Vienna. The software is designed to assist radiologists in the detection of colorectal polyps in CT colonography image data. Version 4.0 includes a significant increase in the performance of the polyp detection algorithm, reducing the number of false positive CAD marks displayed for each patient case.

Dr David Burling, Consultant Gastrointestinal Radiologist and VC Program Director at St. Mark's Hospital, London, UK commented today, "We welcome this latest improvement to Medicsight's ColonCAD product. CAD is now an integral part of our reading strategy in routine clinical practice. It improves interpretation accuracy and is complimentary to workflow."

Internal testing on a dataset of 91 patient cases showed that the ColonCAD API 4.0 maintains the same high levels of sensitivity to the previous version but displays a 50% reduction in false positives, with the CAD now returning a mean of 6.5 false positive marks per patient case*. ColonCAD API 4.0 demonstrates the following sensitivity:

Size of Polyp	Sensitivity
2mm-50mm	85%
6mm-9mm	90%
10mm+ (clinically significant)	92%+

The patient data used in this testing remained independent from the development of the CAD and have been endoscopically validated and reviewed by a panel of expert radiologists to determine the ground truth against which the CAD performance was assessed.

Allan Rowley, Chief Executive of Medicsight, commented, "Previous research has shown Medicsight's ColonCAD significantly improves the performance of radiologists in the detection of polyps in CT colonography image data. The reduction in the numbers of false positives returned by our latest version of CAD is expected to further improve the performance of radiologists, by reducing the number of CAD marks which must be assessed when reviewing a patient dataset."

ColonCAD API 4.0 has been CE Marked and will be available for sale in Europe through Medicsight's network of partners.

More than 17,000 medical and industry professionals from over 95 countries will be attending this year's ECR which is taking place in the Austria Center, Vienna from 6-10 March. Visitors will be able to see demonstrations of the Medicsight ColonCAD software integrated into their partners' 3D advanced visualization workstations at the company's exhibition booth no 506 in Expo E.

* Data on file, Medicsight PLC

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc. is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (AIM: MDST) is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerized tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyze potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualization workstations of several industry-leading imaging equipment partners.

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

Investor & Media enquiries:
KCSA Strategic Communications
Todd Fromer / Garth Russell
Tel: +1 212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com

SOURCE MGT Capital Investments, Inc.

<http://www.mgtci.com>

Copyright (C) 2009 PR Newswire. All rights reserved